CA2730614A1 - Signatures and pcdeterminants associated with prostate cancer and methods of use thereof - Google Patents

Signatures and pcdeterminants associated with prostate cancer and methods of use thereof Download PDF

Info

Publication number
CA2730614A1
CA2730614A1 CA2730614A CA2730614A CA2730614A1 CA 2730614 A1 CA2730614 A1 CA 2730614A1 CA 2730614 A CA2730614 A CA 2730614A CA 2730614 A CA2730614 A CA 2730614A CA 2730614 A1 CA2730614 A1 CA 2730614A1
Authority
CA
Canada
Prior art keywords
pcdeterminants
subject
cancer
sample
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2730614A
Other languages
English (en)
French (fr)
Inventor
Ronald Depinho
Zhihu Ding
Lynda Chin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2730614A1 publication Critical patent/CA2730614A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
CA2730614A 2008-07-16 2009-07-16 Signatures and pcdeterminants associated with prostate cancer and methods of use thereof Abandoned CA2730614A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8128608P 2008-07-16 2008-07-16
US61/081,286 2008-07-16
PCT/US2009/050885 WO2010009337A2 (en) 2008-07-16 2009-07-16 Signatures and pcdeterminants associated with prostate cancer and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2730614A1 true CA2730614A1 (en) 2010-01-21

Family

ID=41551019

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2730614A Abandoned CA2730614A1 (en) 2008-07-16 2009-07-16 Signatures and pcdeterminants associated with prostate cancer and methods of use thereof

Country Status (14)

Country Link
US (3) US20110265197A1 (enExample)
EP (1) EP2318543A2 (enExample)
JP (1) JP2011528442A (enExample)
KR (1) KR20110052627A (enExample)
CN (1) CN102159727A (enExample)
AU (1) AU2009270851A1 (enExample)
BR (1) BRPI0916229A2 (enExample)
CA (1) CA2730614A1 (enExample)
IL (1) IL210681A0 (enExample)
MX (1) MX2011000451A (enExample)
NZ (1) NZ590851A (enExample)
RU (1) RU2011105627A (enExample)
WO (1) WO2010009337A2 (enExample)
ZA (1) ZA201101132B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103733065A (zh) * 2011-06-02 2014-04-16 阿尔玛克诊断有限公司 用于癌症的分子诊断试验
US11091809B2 (en) 2012-12-03 2021-08-17 Almac Diagnostic Services Limited Molecular diagnostic test for cancer

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2598659T3 (en) 2010-07-27 2015-05-26 Genomic Health Inc PROCEDURE FOR USING GENEPRESSION FOR DETERMINING PROSTATE CANCER FORECAST
WO2012061510A2 (en) * 2010-11-03 2012-05-10 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents
WO2012178087A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
CA2840066A1 (en) 2011-06-27 2013-01-03 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with prostate cancer progression and methods of use thereof
WO2013031757A1 (ja) * 2011-08-29 2013-03-07 東レ株式会社 膵癌、乳癌、肺癌又は前立腺癌の検出用マーカー及び検査方法
CA2863040C (en) 2012-01-31 2022-04-19 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
WO2013163134A2 (en) * 2012-04-23 2013-10-31 The Trustees Of Columbia University In The City Of New York Biomolecular events in cancer revealed by attractor metagenes
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US20140011685A1 (en) * 2012-07-03 2014-01-09 Yixin Wang Genomic diagnostics using circulating endothelial cells
AU2013342273A1 (en) * 2012-11-09 2015-05-21 Dana-Farber Cancer Institute, Inc. Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer
KR101456683B1 (ko) * 2013-01-04 2014-11-06 서울대학교산학협력단 폐암 진단용 마커
EP2971054A4 (en) * 2013-03-14 2017-04-12 Otraces Inc. A method for improving disease diagnosis using measured analytes
US20160024592A1 (en) * 2013-03-14 2016-01-28 The Board Of Regents Of The University Of Texas System Single-cell analysis as a sensitive and specific method for early prostate cancer detection
CN105861692A (zh) * 2013-06-24 2016-08-17 复旦大学附属肿瘤医院 研究前列腺癌复发和转移的方法
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
CN105492630A (zh) * 2014-01-03 2016-04-13 皇家飞利浦有限公司 使用靶基因表达的数学建模评价pi3k细胞信号传导途径活性
BR112016017132B1 (pt) 2014-01-28 2024-01-30 Quest Diagnostics Investments Incorporated Métodos para identificar uma zona de célula tipo tronco de câncer, uma zona de transição de adenoma-adenocarcinoma, um tumor de cólon, células-tronco de câncer, um indivíduo com câncer colorretal provável de responder favoravelmente ao tratamento com uma terapia alvejada pela via nf-kb, um indivíduo com perda genômica de 18q/smad4 e de 10q/pten, para diagnosticar um indivíduo com alto grau de adenoma de cólon e adenocarcinoma inicial, e para determinar a probabilidade de um tumor de cólon em um indivíduo passar por uma transformação invasiva se deixado sem tratamento e a probabilidade de um indivíduo com câncer colorretal (crc) responder favoravelmente ao tratamento com uma terapia alvejada pela via tgf-beta, e, kit para identificar uma região de transição de (...).
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
EP3230314B1 (en) 2014-12-08 2023-05-03 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2017062505A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
WO2017079571A1 (en) 2015-11-05 2017-05-11 Arphion Diagnostics Process for the indentication of patients at risk for oscc
US11079745B2 (en) * 2015-11-25 2021-08-03 Lawrence Livermore National Security, Llc Rapid closed-loop control based on machine learning
EP3405896A4 (en) 2016-01-22 2019-09-25 Otraces Inc. SYSTEMS AND METHOD FOR IMPROVED DIAGNOSIS OF ILLNESSES
KR101881874B1 (ko) * 2016-04-29 2018-07-26 한국수력원자력 주식회사 저선량 방사선 조사에 의한 암화 예방 방법
EP3468546A4 (en) 2016-06-09 2020-04-01 Cedars-Sinai Medical Center COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3507360A4 (en) * 2016-08-30 2020-07-29 Beth Israel Deaconess Medical Center Inc. COMPOSITIONS AND TREATMENT METHODS FOR TUMOR SUPPRESSOR-DEFICIENT CANCER
US10487365B2 (en) 2016-09-20 2019-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting expression of lnc-FANCI-2 in cervical cells
CA2984267A1 (en) * 2016-11-01 2018-05-01 Medarchon, Inc. Patient handoff device, system and predictive method
US11312998B2 (en) * 2016-11-07 2022-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selecting therapy for a cancer patient
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11754567B2 (en) 2018-04-30 2023-09-12 City Of Hope Cancer detection and ablation system and method
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP6888123B2 (ja) * 2018-10-15 2021-06-16 イルミナ インコーポレイテッド 深層畳み込みニューラルネットワークを事前訓練するための深層学習ベースの技術
CA3126432A1 (en) * 2019-02-01 2020-08-06 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer
US12320812B2 (en) 2019-02-06 2025-06-03 Bpgbio, Inc. Markers for the diagnosis of biochemical recurrence in prostate cancer
WO2021062261A1 (en) * 2019-09-25 2021-04-01 The Trustees Of Columbia University In The City Of New York Prognostic markers of metastatic cancer
KR102380529B1 (ko) * 2020-04-29 2022-03-31 인제대학교 산학협력단 전이성 전립선 암의 진단 및 예후 예측을 위한 혈중종양세포 기반 바이오 마커 조성물
US12271832B2 (en) * 2021-02-12 2025-04-08 Tempus Ai, Inc. Artificial intelligence engine for directed hypothesis generation and ranking
WO2026078234A1 (en) * 2024-10-10 2026-04-16 Consiglio Nazionale Delle Ricerche Prognostic signature for prostate cancer classification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
US20070248535A1 (en) * 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
EP2674435A3 (en) * 2006-03-24 2014-04-30 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103733065A (zh) * 2011-06-02 2014-04-16 阿尔玛克诊断有限公司 用于癌症的分子诊断试验
EP2715348A4 (en) * 2011-06-02 2015-10-07 Almac Diagnostics Ltd MOLECULAR DIAGNOSTIC TEST FOR CANCER
AU2012261820B2 (en) * 2011-06-02 2017-01-19 Almac Diagnostics Limited Molecular diagnostic test for cancer
CN103733065B (zh) * 2011-06-02 2017-12-15 阿尔玛克诊断有限公司 用于癌症的分子诊断试验
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
US11091809B2 (en) 2012-12-03 2021-08-17 Almac Diagnostic Services Limited Molecular diagnostic test for cancer

Also Published As

Publication number Publication date
CN102159727A (zh) 2011-08-17
MX2011000451A (es) 2011-10-12
US20110265197A1 (en) 2011-10-27
ZA201101132B (en) 2012-07-25
KR20110052627A (ko) 2011-05-18
EP2318543A2 (en) 2011-05-11
IL210681A0 (en) 2011-03-31
US20170299594A1 (en) 2017-10-19
BRPI0916229A2 (pt) 2015-11-03
RU2011105627A (ru) 2012-08-27
AU2009270851A1 (en) 2010-01-21
NZ590851A (en) 2012-08-31
WO2010009337A9 (en) 2010-03-04
JP2011528442A (ja) 2011-11-17
WO2010009337A2 (en) 2010-01-21
WO2010009337A3 (en) 2010-07-22
US20140235479A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
US20170299594A1 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
US20200232988A1 (en) Signatures and determinants associated with prostate cancer progression and methods of use thereof
Klopfleisch et al. Proteome of metastatic canine mammary carcinomas: similarities to and differences from human breast cancer
US20110182881A1 (en) Signature and determinants associated with metastasis and methods of use thereof
US20110119776A1 (en) Methods of diagnosing and prognosing lung cancer
WO2013006495A2 (en) Methods of predicting prognosis in cancer
US20080242742A1 (en) Animal models of pancreatic adenocarcinoma and uses therefor
Pakula et al. Distinct mesenchymal cell states mediate prostate cancer progression
Chun et al. Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis
JP2007523631A5 (enExample)
Donovan et al. Predicting high-risk disease using tissue biomarkers
Tang et al. PRMT5 acts as a tumor suppressor by inhibiting Wnt/β-catenin signaling in murine gastric tumorigenesis
JP5696320B2 (ja) α−アクチニン−４遺伝子のコピー数を指標とした卵巣癌の予後判断の補助方法及び予後判断のためのキット
Grbesa et al. SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape
JP2009502159A (ja) ガン成長ならびにｄｎａ損傷に基づく疾患のマーカーとしてのスネイルの段階的発現
US20040002086A1 (en) Monoclonal antibody for Nkx3.1 and method for detecting the same
Hornick et al. EDUCATION COMMITTEE
MORTON et al. BASIC—LIVER, PANCREAS, AND BILIARY TRACT
Gohlke Molecular analysis of pancreatic cancer metastasis in a genetically engineered mouse model
Caswell The Timing and Molecular Mechanisms of Lung Adenocarcinoma Metastasis
Liang Identifying Novel Genetic Modifiers of P53 Involved in Embryonic Lethality
US20080038729A1 (en) Method For Monitoring The Progress Of Cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150716